Benzinga

AUGUST 3, 2022

Global Blood Therapeutics Inc (NASDAQ: GBT ) shares are soaring in Wednesday's after-hours session following a report suggesting the company is attracting takeover interest. Global Blood Therapeutics is reportedly working with.

52

52

Benzinga

AUGUST 8, 2022

Pfizer Inc. billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT ). per share for Global Blood, roughly a 42.7% Global Blood shares ripped higher in midday trading on Friday after the Wall Street Journal reported Pfizer was in talks to acquire the company.

Banking 52

Banking 52

Law 360 M&A

AUGUST 8, 2022

Pfizer Inc. will acquire sickle cell-drug company Global Blood Therapeutics in a $5.4 billion enterprise value deal shaped by legal advisers Cravath Swaine & Moore LLP, Goodwin Procter LLP and Wachtell Lipton Rosen & Katz, the companies said Monday.

Enterprise Value 40

Enterprise Value 40

Law 360 M&A

SEPTEMBER 9, 2022

Global Blood Therapeutics Inc. billion plan to acquire the sickle cell-drug company, claiming that GBT's top brass made incomplete and misleading disclosures in an attempt to convince shareholders to sign off on the proposed deal. investors have challenged Pfizer's $5.4

40

40

Benzinga

MAY 2, 2023

May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. We believe that combining the Exacis and Eterna technologies de-risks our approach and supports a capital-efficient path to develop highly competitive cancer therapeutics." We are excited to bring this powerful platform into Eterna. Gregory Fiore, M.D.,

Technology 52

Technology 52

Benzinga

NOVEMBER 1, 2023

01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. NASDAQ: NARI ) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it has entered into a definitive agreement to acquire LimFlow, S.A., PT / 4:30 P.M. ET IRVINE, Calif.,

Technology 45

Technology Marketability 45

Benzinga

DECEMBER 25, 2023

26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ: GRCL ), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, today announced it has entered into a definitive agreement to be acquired by AstraZeneca.

Technology 40

Technology Marketability 40